AstraZeneca Breaks Ground on New Small Molecule Drug Plant in Wuxi
Company

AstraZeneca Breaks Ground on New Small Molecule Drug Plant in Wuxi

IASO Biotherapeutics' Fucaso Granted Orphan Drug Designation by SFDA for Multiple Myeloma
CompanyDrug

IASO Biotherapeutics’ Fucaso Granted Orphan Drug Designation by SFDA for Multiple Myeloma

Lepu Medical's MWN109 Gets NMPA Clinical Approval for Diabetes and Obesity
CompanyDrug

Lepu Medical’s MWN109 Gets NMPA Clinical Approval for Diabetes and Obesity

RemeGen's Disitamab Vedotin Receives NMPA Approval for HER2+ Breast Cancer with Liver Metastasis
CompanyDrug

RemeGen’s Disitamab Vedotin Receives NMPA Approval for HER2+ Breast Cancer with Liver Metastasis

NMPA Grants Hengrui Pharmaceuticals Approval for Adebrelimab Combination Trials
CompanyDrug

NMPA Grants Hengrui Pharmaceuticals Approval for Adebrelimab Combination Trials

XtalPi Holdings Plans Acquisition of Re Medical for RMB 250 Million
CompanyDeals

XtalPi Holdings Plans Acquisition of Re Medical for RMB 250 Million

Sino Medical Sciences Gains Mexican Approval for Coronary Balloon Catheters
CompanyMedical Device

Sino Medical Sciences Gains Mexican Approval for Coronary Balloon Catheters

Abogen's ABO2102 mRNA Cancer Vaccine Gets US Clinical Trial Approval
CompanyDrug

Abogen’s ABO2102 mRNA Cancer Vaccine Gets US Clinical Trial Approval

J&J's Tremfya Approved for Ulcerative Colitis in China
CompanyDrug

J&J’s Tremfya Approved for Ulcerative Colitis in China

China's CDE Reveals 93rd Batch of Reference Preparations for GQCE
Policy / Regulatory

China’s CDE Reveals 93rd Batch of Reference Preparations for GQCE

NHC Issues Guidelines for Geriatric Medicine Departments Construction and Management
Policy / Regulatory

NHC Issues Guidelines for Geriatric Medicine Departments Construction and Management

Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales
Company

Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales